Multiple sclerosis (MS) as a chronic, degenerative autoimmune disease of the central
nervous system has a longitudinal and heterogeneous course with increasing treatment …

Background: Multiple sclerosis (MS) quality of care guidelines are consensus-based. The
effectiveness of the recommendations is unknown. Objective: To determine whether clinic …

Background: Time matters in multiple sclerosis (MS). Irreversible neural damage and cell
loss occur from disease onset. The MS community has endorsed a management strategy of …

Abstract On 12 September 2019, the global Patient Reported Outcome for Multiple Sclerosis
(PROMS) Initiative was launched at the 35th Congress of the European Committee for …

Multiple sclerosis (MS) has a longitudinal and heterogeneous course, with an increasing
number of therapy options and associated risk profiles, leading to a constant increase in the …

Significant advancements have been achieved in delineating the progress of the Global
PROMS (PROMS) Initiative. The PROMS Initiative, a collaborative endeavor by the …

Background: As of September 2022, there was no globally recommended set of core data
elements for use in multiple sclerosis (MS) healthcare and research. As a result, data …

We read with interest the publication by Voigt et al. who compiled 24 quality indicators (QIs)
and checklists to document and improve the quality of care for people with multiple sclerosis …

Background Previously, consensus MS care standards were defined by MS specialist
neurologists from 19 countries. We developed, piloted and refined an Excel-based quality …

The need for improved clinical outcome measures in multiple sclerosis trials has been
recognized for two decades, but only recently has the Food and Drug Administration (FDA) …